<DOC>
	<DOC>NCT02776761</DOC>
	<brief_summary>This is a single-center, randomized, single-blinded study of the HTNV DNA vaccine alone, PUUV DNA vaccine alone, and mixed HTNV/PUUV DNA vaccines delivered IM by the needle-free PharmaJet Stratis DSJI device.</brief_summary>
	<brief_title>A Single-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Hantaan Virus DNA Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult male or nonpregnant, nonlactating female, ages 1849 (inclusive) at the time of screening Have provided written informed consent before screening Free of clinically significant health problems as determined by pertinent medical history and clinical examination prior to entry into the study Available and able to participate for all study visits and procedures Females, if not abstinent, are known to be at least 1 year postmenopausal (defined as no menses for 12 consecutive months) or willing to use an effective method of contraception (eg, hormonal contraception to include oral and implantable options, diaphragm, cervical cap, intrauterine device, condom, or anatomical sterility [self or partner]) for the duration of study participation (from the date of screening) until at least 3 months after the last injection Negative hantavirus PsVNA test result at screening History or serologic evidence of prior infection with any hantavirus or prior participation in an HTNV or PUUV vaccine trial History of severe local or systemic reactions to any vaccination or a history of severe allergic reactions Ongoing participation in another clinical trial (subjects continuing through Day 365 will not join other new studies until their final visit) Receipt of licensed vaccines within 14 days before or after immunization (30 days for live vaccines) Ability to observe possible local reactions at the eligible injections sites (deltoid region) is, in the opinion of the investigator, unacceptably obscured due to a physical condition or permanent body art Acute or chronic, clinically significant hematologic, pulmonary, cardiovascular, or hepatic or renal functional abnormality as determined by the investigator based on medical history, physical exam, and/or laboratory screening test Pregnant or lactating female, or female who intends to become pregnant during the study period Administration of immunoglobulins and/or any blood products within the 120 days preceding study entry or planned administration during the study period Blood donation for human use (eg, American Red Cross or other similar blood drives) within the 56 days preceding study entry or planned administration during the study period Any confirmed evidence of hepatitis B or C infection Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection Administration of chronic (defined as more than 14 days) immunosuppressants or other immunemodifying drugs within 6 months of study entry For corticosteroids, this will mean prednisone, or equivalent, greater than or equal to 0.5 mg/kg/day Intranasal, inhaled, and topical steroids are allowed (daily inhaled steroids for treatment of asthma are NOT allowed) Any chronic or active neurologic disorder, including seizures and epilepsy, excluding a single febrile seizure as a child Suspected or known current alcohol and/or illicit drug abuse Unwilling to allow storage and use of blood for future hantavirusrelated research Any other significant finding that in the opinion of the investigator would increase the risk of the individual having an adverse outcome from participating in this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>